Final Program

82 SUNDAY • MAY 15
P824
Facilitator:
P825
P826
P827
P828
P829
P830
P831
Facilitator:
P832
P833
P834
P835
Legionella Pneumonia: Five Years’ Experience in an Inner-City
Hospital in New York City. Comparison Between Sporadic and
Outbreak Cases/H.R.T. Hashmi, G. Diaz-Fuentes, S. Lakshmi, F.
Peteresen-Fitzpatrick, M. Khaja, Bronx, NY, p.A2100
M. Prickett, MD, MPH, Chicago, IL
A Case Series of Legionnaires’ Disease Outbreak in the Bronx,
NY in 2015/J.-T. Chen, R.I. Asad, H.B. Gershengorn, Bronx, NY,
p.A2101
Clinical Disease Severity Scores and a Legionella Outbreak in
the Bronx, NY: An Institutional Experience/G. Harris, M.
Langston, V. Reddy, C. Coyle, New York, NY, p.A2102
Legionnaire’s Disease in Eight Potentially
Epidemiologically-Linked Patients During Two Recent New
York City Outbreaks: Case Reports and Literature Review/S.
Fahme, M. O’Donnell, New York City, NY, p.A2103
Variation in Detection and Coverage of Resistant Pathogens in
Hospitalized Veterans with Pneumonia at 128 Medical
Centers/B.E. Jones, K.A. Brown, M.M. Jones, B. Huttner, T.
Greene, B. Sauer, K. Madaras-Kelly, M. Rubin, M.B. Goetz, M.
Samore, Salt Lake City, UT, p.A2104
Anaerobic Bacteria Dominate the Airway Microbiome of
Patients with Acute Lung Injury Following Burn and Inhalation
Injury/D.M. Walsh, S.D. McCullough, S. Yourstone, J.J. Kahle,
S.W. Jones, C.D. Jones, I. Jaspers, D. Diaz-Sanchez, Chapel Hill,
NC, p.A2105
Neutrophil Extracellular Traps Are Associated with Disease
Severity in Chronic Obstructive Pulmonary Disease/C. Fong,
A.J. Dicker, M. Crichton, G. Suarez-Cuartin, O. Sibila, S. Schembri,
S. Marshall, C.N.A. Palmer, J.D. Chalmers, Dundee, United
Kingdom, p.A2106
Relation Between Biomarkers on Admission, Radiologic
Abnormalities and Risk Score in Patients with Community
Acquired Pneumonia (CAP)/R. Duijkers, W.G. Boersma, Alkmaar,
Netherlands, p.A2107
M.I. Restrepo, MD, MSc, San Antonio, TX
Diagnostic and Prognostic Utility of Procalcitonin in Patients
Presenting to the Emergency Department with Dyspnea/
G.A. Alba, Q.A. Truong, H.K. Gaggin, P.U. Gandhi, B. De
Berardinis, L. Magrini, E.K. Bajwa, S. Di Somma, J.L. Januzzi,
Boston, MA, p.A2108
A Retrospective Study Comparing Procalcitonin with
Physiological Severity Score in Community Acquired
Pneumonia in a Middle Eastern Tertiary Centre/J.A. Palaki, A.M.
Maliyakkal, L. Ahmed, M. Ganeshdas, N.M. Shaath, Al Wakra,
Qatar, p.A2109
Impact and Safety of a Procalcitonin-Based Algorithm on
Antibiotic Use in Hospitalized Patients with Lower Respiratory
Tract Infections/G. Soucy, E. Roy Richard,, G. Soucy, J.-P. Lafrance,
K. Chagnon, R. Robitaille, K. Weiss, Quebec, Canada, p.A2110
Is Neutrophil to Lymphocyte Ratio Useful Prognostic Marker
for Patients with Community Acquired Pneumonia/C. Son,
Busan, Korea, Republic of, p.A2111
P836
P837
P838
Facilitator:
P839
P840
P841
P842
P843
P844
P845
Facilitator:
P846
P847
Streamlining Antibacterial Drug Development Programs to
Address Unmet Medical Need: Patient and Provider Attitudes
on a Modified Benefit-Risk Calculus/T. Holland, S. Mikita, A.
Corneli, J. Roberts, J. McCall, D. Collyar, J. Santiago, R. Tiernan,
Durham, NC, p.A2112
Influence of Flexible Bronchoscopy on Antibiotic Selection in
the Inpatient Setting/E.E. O’Shea, M. Davis, S. Davis, Worcester,
MA, p.A2113
Beta-Lactam Plus Macrolides or Beta-Lactam Alone for
Community-Acquired Pneumonia: Systematic Review and
Meta-Analysis/N. Horita, A. Narita, M. Ikeda, K. Nakashima, R.
Ushio, H. Watanabe, K. Nagai, Y. Shibata, K. Tashiro, H.
Nagakura, T. Tsukahara, M. Yamamoto, T. Sato, T. Kaneko,
Yokohama, Japan, p.A2114
J.A. Ramirez, MD, Louisville, KY
Respiratory Fluoroquinolones Versus b-Lactams for
Non-Intensive Care Unit Hospitalized Community-Acquired
Pneumonia Patients: A Pooled Analysis/S. Liu, X. Tong, H. Fan,
Chengdu, China, p.A2115
SOLITAIRE-IV: Results of a Phase 3 IV to Oral Trial in Adults
with Community-Acquired Bacterial Pneumonia Comparing
Solithromycin to Moxifloxacin/T.M. File, Jr., B. Rewerska, C.M.
Tanaseanu, V. Mihailovic-Vucinic, J.R. Gonong, B.D. Jamieson, D.
Taylor, A. Sheets, K. Keedy, D.W. Oldach, P. Fernandes, Akron,
OH, p.A2116
Ceftaroline Activity Against MDR Streptococcus Pneumoniae
Subsets from United States Medical Centers (2014)/D.J. Farrell,
R.E. Mendes, R.K. Flamm, H.S. Sader, R.N. Jones, North Liberty,
IA, p.A2117
Clinical Efficacy and Safety of High-Dose Doripenem in
Japanese Patients with Pneumonia/K. Naito, K. Yatera, S.
Noguchi, K. Akata, K. Yamasaki, T. Kawanami, T. Kido, H.
Ishimoto, H. Mukae, Kitakyusu, Japan, p.A2118
An Exploration of De-Escalation Strategies in Hospitalized
Patients with Community Acquired Pneumonia/F. Papik, G.
Nair, P.R. Yeturu, M.J. Fazzari, D. Kurbanov, M.S. Niederman,
Mineola, NY, p.A2119
Current Management and Associated Risks of Pediatric
Patients Diagnosed with Community-Acquired Pneumonia
(CAP) in Mongolia/G. Dorj, Ulaanbaatar, Mongolia, p.A2120
Social Factors on Hospitalization Period of Elderly Patients with
Pneumonia in Japan/Y. Fuseya, Y. Yamamoto, T. Takahashi, D.
Naito, K. Shima, K. Takahashi, N. Sakai, Otsu, Shiga, Japan, p.A2121
R.G. Wunderink, MD, Chicago, IL
Risk Factors to Early Mortality Among Dead Patients by
Pneumonia Coming from Community/A. Ceccato, M. Toranzo,
M. Galperin, L. Cristaldo, G. Yusti, A. Gonzalez, A. Monteverde,
Palomar, Argentina, p.A2122
Modelling Symptomatic Recovery from Community Acquired
Pneumonia Reveals the Association of Age and Smoking with
Extent of Recovery/D. Wootton, L. Keogan, S. Gordon, O. Eneje,
J. Court, L. Macfarlane, S. Wilks, M. Woodhead, P. Diggle,
Liverpool, United Kingdom, p.A2123
ATS 2016 • San Francisco